Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma
This study is a randomized, controlled, open-label, multicenter Phase III clinical trial, designed to evaluate the efficacy and safety of neoadjuvant toripalimab in combination with nab-paclitaxel and platinum versus neoadjuvant docetaxel in combination with cisplatin and 5-fluorouracil (DCF) in the treatment of resectable locally advanced esophageal squamous cell carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
DRUG: 3 cycles (Toripalimab + chemotherapy)|DRUG: 3 cycles（DCF）
Pathological complete response rate (pCR), Pathological detection after surgery within 1 month
Major pathological response rate (MPR), Pathological detection after surgery within 1 month|objective response rate (ORR), From enrollment to the period before surgery (4-6 weeks after the third cycle of treatment).|event-free survival (EFS), from randomization to disease progression that makes surgery impossible, postoperative disease progression, local or distant recurrence, or death from any cause (whichever occurs first，assessed up to 60 months)|overall survival, from randomization to death from any cause，assessed up to 60 months|Adverse events, form date of enrollment until the end of the study, assessed up to 60 months
This study is a randomized, controlled, open-label, multicenter Phase III clinical trial, designed to evaluate the efficacy and safety of neoadjuvant toripalimab in combination with nab-paclitaxel and platinum versus neoadjuvant docetaxel in combination with cisplatin and 5-fluorouracil (DCF) in the treatment of resectable locally advanced esophageal squamous cell carcinoma